A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2015
At a glance
- Drugs FP 1039 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Dec 2015 Results published in the Annals of Oncology
- 06 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Nov 2010 Planned end date changed from 1 Sep 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.